HealthDay - THURSDAY, Feb. 24 (HealthDay News) -- The cancer drug Herceptin produces significantly longer disease-free survival in women with an aggressive type of early-stage breast cancer who take the drug for a year after standard chemotherapy, a new study suggests.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.